{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:41:43Z","timestamp":1790991703377,"version":"4.1.0"},"reference-count":19,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,3,3]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>In a multicenter, randomized phase 3 trial, MPR-R was not superior over MPT-T with respect to response rate, PFS, and OS. Grade 3\/4 hematologic toxicity requiring growth factor support occurred with MPR-R vs clinically significant neuropathy with MPT-T.<\/jats:p>","DOI":"10.1182\/blood-2015-11-679415","type":"journal-article","created":{"date-parts":[[2016,1,22]],"date-time":"2016-01-22T20:42:34Z","timestamp":1453495354000},"page":"1109-1116","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":106,"title":["Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma"],"prefix":"10.1182","volume":"127","author":[{"given":"Sonja","family":"Zweegman","sequence":"first","affiliation":[{"name":"Department of Hematology, Cancer Center Amsterdam, Vrije Universiteit Medical Center, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bronno","family":"van der Holt","sequence":"additional","affiliation":[{"name":"Hemato Oncologie Volwassenen Nederland Data Center, Erasmus Medical Center Cancer Center, Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf-Henrik","family":"Mellqvist","sequence":"additional","affiliation":[{"name":"Section of Hematology and Coagulation, Department of Medicine, Sahlgrenska University Hospital, Gotheborg, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Salomo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Rigshospitalet, Copenhagen, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard M. J.","family":"Bos","sequence":"additional","affiliation":[{"name":"Department of Hematology, Maastricht University Medical Center, Maastricht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark-David","family":"Levin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heleen","family":"Visser-Wisselaar","sequence":"additional","affiliation":[{"name":"Hemato Oncologie Volwassenen Nederland Data Center, Erasmus Medical Center Cancer Center, Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Hansson","sequence":"additional","affiliation":[{"name":"Division of Hematology and Transfusion Medicine, Skane University Hospital, Lund, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette W. G.","family":"van der Velden","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Martini Ziekenhuis, Groningen, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Deenik","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Tergooi Ziekenhuizen, Blaricum, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Gruber","sequence":"additional","affiliation":[{"name":"Center of Hematology, Karolinska Institute, Stockholm, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juleon L. L. M.","family":"Coenen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Isala, Zwolle, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torben","family":"Plesner","sequence":"additional","affiliation":[{"name":"Department of Hematology, Vejle Hopital, Vejle, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia K.","family":"Klein","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Meander Medisch Centrum, Amersfoort, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bea C.","family":"Tanis","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Groene Hart Ziekenhuis, Gouda, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian L.","family":"Szatkowski","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hematology and Palliative Care, F\u00f8rde Central Hospital, F\u00f8rde, Norway;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf E.","family":"Brouwer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Reinier de Graaf Ziekenhuis, Delft, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthijs","family":"Westerman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Medisch Centrum Alkmaar, Alkmaar, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. (Rineke) B. L.","family":"Leys","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Maasstad Ziekenhuis, Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harm A. M.","family":"Sinnige","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Jeroen Bosch Ziekenhuis, Den Bosch, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar","family":"Hauk\u00e5s","sequence":"additional","affiliation":[{"name":"Department of Hematology, Stavanger University Hospital, Stavanger, Norway;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaas G.","family":"van der Hem","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Zaans Medisch Centrum, Zaandam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc F.","family":"Durian","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Tweesteden Ziekenhuis, Tilburg, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. (Vera) J. M.","family":"Mattijssen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Rijnstate Ziekenhuis, Arnhem, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels W. C. J.","family":"van de Donk","sequence":"additional","affiliation":[{"name":"Department of Hematology, Cancer Center Amsterdam, Vrije Universiteit Medical Center, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian J. P. L.","family":"Stevens-Kroef","sequence":"additional","affiliation":[{"name":"Department of Genetics, Radboud University Medical Center, Nijmegen, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[{"name":"Department of Hematology, Erasmus Medical Center Cancer Center, Rotterdam, The Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Waage","sequence":"additional","affiliation":[{"name":"Department of Hematology, St Olavs Hospital and Norwegian University of Science and Technology and KG Jebsen Myeloma Research Center, Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2019111721173733900_B1","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1182\/blood-2011-03-341669","article-title":"Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials.","volume":"118","author":"Fayers","year":"2011","journal-title":"Blood"},{"issue":"9594","key":"2019111721173733900_B2","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"issue":"22","key":"2019111721173733900_B3","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2008.21.0948","article-title":"Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01\/01 trial.","volume":"27","author":"Hulin","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9513","key":"2019111721173733900_B4","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"issue":"19","key":"2019111721173733900_B5","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1200\/JCO.2009.26.1610","article-title":"Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.","volume":"28","author":"Wijermans","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111721173733900_B6","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1182\/blood-2009-08-237974","article-title":"Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.","volume":"116","author":"Waage","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2019111721173733900_B7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1600-0609.2010.01524.x","article-title":"Addition of thalidomide to oral melphalan\/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.","volume":"86","author":"Beksac","year":"2011","journal-title":"Eur J Haematol"},{"issue":"9","key":"2019111721173733900_B8","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"issue":"27","key":"2019111721173733900_B9","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1200\/JCO.2006.05.6689","article-title":"Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring.","volume":"24","author":"Mileshkin","year":"2006","journal-title":"J Clin Oncol"},{"issue":"28","key":"2019111721173733900_B10","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1200\/JCO.2007.12.3463","article-title":"Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.","volume":"25","author":"Palumbo","year":"2007","journal-title":"J Clin Oncol"},{"issue":"19","key":"2019111721173733900_B11","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma.","volume":"366","author":"Palumbo","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111721173733900_B12","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1200\/JCO.2012.41.6180","article-title":"Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.","volume":"31","author":"San Miguel","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111721173733900_B13","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111721173733900_B14","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.3324\/haematol.2011.056176","article-title":"Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders.","volume":"97","author":"Ross","year":"2012","journal-title":"Haematologica"},{"issue":"11","key":"2019111721173733900_B15","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1182\/blood-2014-12-613927","article-title":"Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma.","volume":"126","author":"Stewart","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2019111721173733900_B16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2011-06-357038","article-title":"The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis.","volume":"119","author":"Morgan","year":"2012","journal-title":"Blood"},{"issue":"21","key":"2019111721173733900_B17","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.1158\/1078-0432.CCR-12-3211","article-title":"Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment.","volume":"19","author":"Morgan","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2019111721173733900_B18","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S1470-2045(13)70609-0","article-title":"Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.","volume":"15","author":"Palumbo","year":"2014","journal-title":"Lancet Oncol"},{"issue":"3","key":"2019111721173733900_B19","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S1470-2045(14)70001-4","article-title":"Lenalidomide and second malignancies in myeloma patients.","volume":"15","author":"Pratt","year":"2014","journal-title":"Lancet Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/127\/9\/1109\/1395773\/1109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/127\/9\/1109\/1395773\/1109.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T21:17:47Z","timestamp":1574025467000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/127\/9\/1109\/126469\/Melphalan-prednisone-and-lenalidomide-versus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,3]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,3,3]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2015-11-679415","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,3]]}}}